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One of the most prevalent complications of pregnancy is preeclampsia, a hypertensive disorder which is a leading cause of
maternal and perinatal morbidity and premature birth with no eﬀective pharmacological intervention. While the underlying
cause is unclear, it is believed that placental ischemia/hypoxia induces the release of factors into the maternal vasculature and lead
to widespread maternal endothelial dysfunction. Recently, HO-1 has been shown to downregulate two of these factors, reactive
oxygen species and sFlt-1, and we have reported that HO-1 induction attenuates many of the pathological factors of placental
ischemia experimentally. Here, we have examined the direct eﬀect of HO-1 and its bioactive metabolites on hypoxia-induced
changesinsuperoxideandsFlt-1inplacentalvascularexplantsandshowedthatHO-1anditsmetabolitesattenuatetheproduction
of both factors in this system. These ﬁndings suggest that the HO-1 pathway may be a promising therapeutic approach for the
treatment of preeclampsia.
1.Introduction
Preeclampsia is a pregnancy-speciﬁc hypertensive disorder
classically characterized by proteinuria and edema after the
twentieth week of gestation [1]. Preeclampsia is a common
complication of pregnancy, with an incidence of ∼5–10%
of all pregnancies [2]. Though the underlying mechanisms
of preeclampsia are not well understood, a central factor
believed to be important in the development of the disease
is placental ischemia and hypoxia which result from a failure
of the maternal uterine vasculature to remodel into high-
capacitance vessels, leading to placental hypoperfusion [3–
5]. In response to hypoxia, the placenta begins to produce
a number of soluble factors which are secreted into the
maternal circulation. Once, in circulation, these factors
induce widespread maternal endothelial dysfunction, one of
the key hallmarks of this disorder [6, 7]. There are a number
of molecular pathways which are involved in the cascade
fromplacentalischemiatomaternalendothelialdysfunction.
Twopathwayswhichhavebeenthesubjectofintenseresearch
are the production of the soluble form of the vascular
endothelial growth factor (VEGF) receptor-denominated
soluble fms-like tyrosine kinase (sFlt-1) and the production
of placental hypoxia-induced reactive oxygen species (ROS).
VEGF signaling is necessary for endothelial health and
maintenance [8]. When, in circulation, sFlt-1 binds to free
VEGF and placental growth factor (PlGF) sequestering them
and making them unavailable for proper signaling [9]. sFlt-
1 can be directly induced by hypoxia through the actions
of HIF-1α and has been shown to be produced by human
placental trophoblasts and villi in response to decreased
oxygen [10–12]. It has also been shown to be produced in
the placenta during preeclampsia and is found to be elevated
in the circulation of preeclamptic women, often before the
onset of maternal symptoms [13, 14]. In addition, numerous
experimental models have demonstrated the importance of
sFlt-1 overexpression in the development of preeclampsia
[15–18]. A second factor implicated in the pathophysiology
of preeclampsia is oxidative stress. Oxidative stress has
been shown to be elevated in both the placenta and the2 International Journal of Hypertension
maternal vasculature of women with preeclampsia [19–
21]. The symptoms associated with experimental rodent
placental hypoperfusion have also shown to be attenuated
by either the superoxide dismutase mimetic Tempol or the
NADPH oxidase inhibitor apocynin [22, 23]. This suggests
that oxidative stress, at least partially induced by NADPH
oxidase, is a crucial factor in the symptomatic manifestation
of preeclampsia.
One potential palliative agent suggested for the normal-
izationofthese twopathwaysis theenzyme hemeoxygenase-
1 (HO-1). HO-1 typically catalyzes the rate-limiting step in
the heme salvage pathway, converting the prooxidant heme
to biliverdin, which is then rapidly converted by biliverdin
reductasetobilirubin,aknownantioxidant[24,25].Asaside
product,HO-1releasescarbonmonoxide, avasodilator[26].
Recently, it has been reported that HO-1 could negatively
regulateVEGForinterferon-γ-inducedsFlt1-releaseinvitro.
Furthermore, CO could directly act in a similar manner
[27]. Also, we have recently demonstrated that induction of
HO-1 in a rodent placental ischemia model attenuated the
associated hypertension and angiogenic imbalance [28]. In
the present work, we have extended this previous work to
examine the direct eﬀects of HO-1 and its byproducts CO
and bilirubin on hypoxia-induced oxidative stress and sFlt-1
production.
2.MaterialsandMethods
2.1. Animals. Timed pregnant Sprague-Dawley rats were
obtained from Harlan, Inc. (Indianapolis, Ind). All animal
protocols were approved by The University of Mississippi
Medical Center Institutional Animal Care and Use Commit-
tee and followed the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals. Animals were
maintained at constant temperature (23◦C) with a 12:12h
light:dark cycle. On day 19 of gestation, the animals were
sacriﬁced by pneumothorax and cardiac excision followed by
tissue harvest.
2.2. Placental Explants. Placental explants were cultured as
described previously [29]. Brieﬂy, after tissue excision, pla-
centas were immediately placed into cold Dulbecco’s Phos-
phate Buﬀered Saline (Sigma, St. Louis, Mo). The mesome-
trium and decidua were carefully removed, and villous bun-
dles from the trophospongium and labyrinth were excised.
The villous explants were plated in 24-well cell culture plates
coated with 0.2mL of Matrigel Matrix Basement Mem-
brane from BD Bioscience (Bedford, Mass). Explants were
grown in Dulbecco’s Modiﬁed Eagle’s Media-Ham’s F-12
supplemented with 10% FBS, 100μg/mL streptomycin, 100
U/mL penicillin, and 25μg/mL ascorbic acid as previously
described [30]. The explants were maintained at constant
oxygen tensions of either 6% or 1% in double gas incubators
purged with nitrogen.
2.3.ExperimentalProtocol. Explantswererandomlyassigned
into control and experimental groups. Control explants were
incubated in media with no supplementation. The HO-
1 inducer cobalt (III) protoporphyrin IX chloride (CoPP,
Frontier Scientiﬁc, Logan, Utah) was prepared in 0.1M
NaOH in saline, and the pH was adjusted to a ﬁnal pH of
8.5 CoPP was utilized at a ﬁnal concentration in culture
of 20μM. CORM-3 has been previously described [31]a n d
was prepared in media immediately before use at a ﬁnal
concentration of 40μM. Bilirubin was utilized at a ﬁnal
concentration of 100μM. At 48 hours after treatment, the
cell culture media was removed from the explants and
both media and tissue were frozen for further analysis. A
minimum of 5 samples were obtained for every experimental
group.
2.4. Western Blotting. Total intracellular protein was extract-
ed by 5X repeated freeze-thaw lysis in FT buﬀer (600mM
KCl, 20mM Tris-Cl, pH 7.8, 20% glycerol, 0.4mg/mL Pefa-
bloc, 10μg/mL leupeptin, 10μg/mL pepstatin, and 5μg/mL
aprotinin) [32]. Protein concentration was determined by
Bradford assay (Bio-Rad). For western blots, 30μgo fp r o t e i n
was subjected to SDS-PAGE on 4–20% gradient SDS-poly-
acrylamide gels (Bio-Rad). Membranes were blocked with
Odyssey blocking buﬀer (LI-COR, Lincoln, Neb) for two
hours at room temperature. Primary incubation was under-
taken overnight at 4◦C with a rabbit anti-HO-1 polyclonal
antibody (StressGen, Vancouver, Calif) at 1:2000 and a
mouseanti-β-actinantibody(Gentest)at1:5000.Secondary
antibody incubation was done with Alexa Fluor 680 goat
anti-rabbit (Molecular Probes) and IRDye 800 goat anti-
mouse IgG (Rockland) for one hour at room temperature.
Fluorescence was detected on an Odyssey infrared imager
(LI-COR) for simultaneous detection of both species. Blot
analysis was performed with the supplied Odyssey software,
and HO-1 was normalized to β-actin, with n = 6i ne a c h
group.
2.5. Measurement of Superoxide by DHE. DHE ﬂuorescence
assays were carried out as previously described [33]. Individ-
ual wells of a black 96-well microtiter plate were ﬁlled with
200uL of 5μM DHE (Invitrogen) diluted into phosphate
buﬀered saline. Fluorescence was monitored by excitation at
510nmandemissionat610nm.Fluorescencewasmonitored
every 2 minutes for a total of one hour and the resulting
measurements averaged over the life of the experiment. For
each group, n = 7–13. Fluorescence was normalized to the
average of normoxic controls. Statistical comparisons were
performed by one-way ANOVA.
2.6. sFlt-1 Measurement. Total protein concentration of the
cell culture supernatants was determined by the Bicin-
choninic Acid (BCA) assay (Pierce, Rockford, Ill) using bo-
vine serum albumin (BSA) as a standard. Measurement of
s-Flt1 was performed by sandwich ELISAs (R&D Systems,
Minneapolis, Minn) according to manufacturer protocols.
The plates were read on a Tecan GENios microplate reader,
and quantitation was performed with Megellan version 4.1
software. sFlt-1 levels were normalized to the total amount
of media protein, and the results graphed with Origin ProInternational Journal of Hypertension 3
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Figure 1: Hypoxia decreases HO-1 expression in placental villous
explants, which can be restored by CoPP. Placental villous explants
were incubated for 48 hours under 6% (normoxic) or 1% (hypoxic)
oxygen to simulate the oxygen tension in a health and preeclamptic
placenta. As assayed by western blot normalized to β-actin, in
response to hypoxia treatment, there was an approximate 30%
reduction in the tissue levels of HO-1. Cobalt protoporphyrin
(CoPP), while having no signiﬁcant eﬀect under hypoxic condi-
tions, fully restored HO-1 expression in the hypoxic villi. Statistical
signiﬁcance at the P<0.05 level is indicated by “∗”v e r s u s
normoxic controls and “#” versus hypoxic controls.
8 (Microcal), which was also used for all statistical analyses.
Statistical signiﬁcance was determined by one-way ANOVA,
with a signiﬁcance threshold of P<0.05.
3. Results
3.1.HypoxiaSuppressesHO-1ExpressioninPlacentalVilliand
CoPP Treatment Restores Normal HO-1 Levels. In order to
assess the eﬀe c to fh y p o x i aa n dC o P Po nH O - 1e x p r e s s i o n
in placental villi, villous explants were excised from the
trophospongiumandlabyrinthofrodentplacentasonday19
of gestation. These tissues were cultured on synthetic base-
ment membrane in either 6% (normoxic) or 1% (hypoxic)
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Figure 2: HO-1 and bilirubin suppress hypoxia-induced increases in
superoxide production. In response to culture in hypoxic conditions,
there is a signiﬁcant ∼60% increase in the level of superoxide gen-
erated by the placental explants as assayed by dihydroxyethidium
(DHE) ﬂuorescence. Administration of CoPP had no signiﬁcant
eﬀect on normoxic explants but completely attenuated the hypoxia-
induced increase seen in the control explants. Exogenous applica-
tion of bilirubin (Bili) had a signiﬁcant attenuation of superoxide
in both the normoxic and hypoxic samples when compared to their
respective controls. Statistical signiﬁcance at the P<0.05 level is
indicated by “∗” versus normoxic controls and “#” versus hypoxic
controls.
oxygen, reﬂecting the approximate oxygen tension of a
normal and hypoxic placenta, respectively. As can be seen in
Figure 1,at48hours,villousbundlesinthehypoxicexhibited
an approximate 30% reduction in their β-actin normalized
HO-1 expression (6% = 1 ± 0.11 versus 1% = 0.69 ± 0.02,
P<0.05). In response to CoPP, there was no signiﬁcant
diﬀerence in the expression of HO-1 in the 6% treated group
(0.89 ± 0.08). When CoPP was administered to villi exposed
to1%oxygen,however,therewasasigniﬁcantnormalization
of HO-1 expression when compared to hypoxic controls
(1% = 0.69±0.02versus1%+CoPP = 1.07±0.08,P<0.05),
indicatingthatCoPPcanrestoreHO-1expressioninhypoxic
villi.
3.2. HO-1 Induction and the HO-1 Byproduct Bilirubin
Attenuate Hypoxia-Induced Superoxide in Placental Villous
Bundles. We next assessed the eﬀects of both HO-1 levels
and the direct eﬀect of the HO-1 product bilirubin, a known
antioxidant, on hypoxia-induced superoxide production. As
seen in Figure 2, in response to hypoxic exposure, there
is a signiﬁcant increase in the tissue levels of superoxide
of approximately 60% as determined by dihydroethidium
ﬂuorescence (6% = 1 ± 0.03 versus 1% = 1.63 ± 0.19, P<
0.05). Administration of CoPP had no signiﬁcant diﬀerence
under normoxic conditions (0.86±0.06), but hypoxic tissues
treated with CoPP exhibited a marked decrease in DHE4 International Journal of Hypertension
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Figure 3: HO-1 induction, CO, and Bilirubin attenuate hypoxia-
induced sFlt-1 secretion. In response to hypoxic incubation, placen-
tal explants demonstrate a signiﬁcant increase in the production
of sFlt-1 when compared to normoxic controls. Administration of
CoPP signiﬁcantly attenuated sFlt-1 released under both normoxic
and hypoxic conditions. Bilirubin, while having no eﬀect under
normoxic conditions, slightly but signiﬁcantly decreased sFlt-1
release when compared to hypoxic controls. Administration of
a CO-releasing molecule (CORM) again had no eﬀect under
normoxic conditions but signiﬁcantly attenuated sFlt-1 release in
hypoxic explants. Statistical signiﬁcance at the P<0.05 level is
indicated by “∗” versus normoxic controls and “#” versus hypoxic
controls.
ﬂuorescence when compared to hypoxic controls (1% =
1.63 ± 0.19 versus 1% + CoPP = 1.01 ± 0.14, P<0.05).
Incubation with bilirubin had a marked eﬀect on detected
superoxide in both normoxic and hypoxic tissues. Under 6%
oxygen, there was a signiﬁcant decrease in DHE ﬂuorescence
when compared to normoxic controls (6% = 1 ± 0.03
versus 6% + Bili = 0.040 ± 0.11, P<0.05). A similar
level of DHE ﬂuorescence was seen in hypoxic tissues, which
were also signiﬁcantly diﬀerent from their hypoxic controls
(1% = 1.63 ±0.19 versus 1%+Bili = 0.54 ±0.15, P<0.05).
ThesedatasuggestthatbothHO-1andbilirubinsigniﬁcantly
attenuate hypoxia-induced superoxide in placental villi.
3.3.HO-1andItsByproductsAttenuateHypoxia-InducedsFlt-
1P r o d u c t i o ni nP l a c e n t a lV i l l i . We also wished to determine
what eﬀect HO-1 and its byproducts would have on the
hypoxia-induced production of sFlt-1. As seen in Figure 3,i n
response to hypoxia treatment, secreted sFlt-1 is signiﬁcantly
increased in response to hypoxia exposure (6% = 1649 ±
12.1pg/mg versus 1% = 1854 ± 35pg/mg, P<0.05).
Administration of CoPP decreased the amount of sFlt-1
secreted under both normoxic (6% = 1649 ± 12.1pg/mg
versus 6% + CoPP = 1477 ± 54pg/mg, P<0.05) and
hypoxic (1% = 1854 ± 35pg/mg versus 1349 ± 32pg/mg,
P<0.05) conditions when compared to their respective
controls. While bilirubin had no signiﬁcant eﬀect on sFlt-1
under normoxic conditions (1753 ± 56pg/mg), in hypoxia-
exposed explants, there was a signiﬁcant decrease in the
production of sFlt-1 when compared to hypoxic controls
(1% = 1854 ± 35pg/mg versus 1542 ± 76pg/mg, P<0.05).
Similarly, administration of a CO donor molecule had no
signiﬁcanteﬀectontheproduction ofsFlt-1undernormoxic
conditions (6% = 1649 ± 12.1pg/mg versus 6% + CORM =
1542 ± 53pg/mg) but exhibited a marked attenuation of
sFlt-1 under hypoxic conditions (1% = 1854 ± 35pg/mg
versus 1392 ± 107pg/mg, P<0.05). Collectively, these data
suggestthatHO-1throughbothCOandbilirubinsuppresses
hypoxia-induced sFlt-1 in placental villi.
4. Discussion
Preeclampsia remains a major health concern, aﬀecting at
least one out of every twenty pregnancies [34]. Besides the
immediate risk for mother and fetus, there is increasing
evidence that preeclampsia confers increased risk for cardio-
vascular complications to the oﬀspring in later life [35]. One
of the major roadblocks in the management of preeclampsia
is the lack of an eﬀective pharmacological intervention for
its treatment. A potential therapy which has been proven
eﬀective in numerous experimental forms of hypertension is
the manipulation of the HO-1 pathway [36–39].
HO-1 is hypothesized to attenuate hypertension through
multiple pathways. HO-1 produces two bioactive com-
pounds as products of heme metabolism: CO and bilirubin.
Bilirubin has been shown in numerous systems to function
as a powerful antioxidant [24, 25]. As it is recognized that
production of reactive oxygen species is a major component
of varied forms of hypertension, moderate increases in
bilirubin could act to decrease overall oxidative stress. CO
acts as a potent vasodilator, functioning in a manner similar
to endothelium-derived relaxing factor [26]. Of particular
interest to preeclampsia, HO-1 and CO have been shown
to directly inhibit production of VEGF and interferon-γ-
induced secretion of sFlt-1 [27]. Additionally, it has been
reported that CO derived from HO-1 in vascular smooth
muscle could inhibit production of endothelin-1 [40], a
protein shown to be a ﬁnal common pathological factor in
several experimental models of preeclampsia.
We have recently demonstrated that induction of the
HO-1 pathway could signiﬁcantly attenuate the preeclamp-
sia-like pathological manifestations associated with experi-
mental placental ischemia in the rodent. Speciﬁcally, HO-
1 attenuated the associated hypertension, with concomi-
tant decreases in placental sFlt-1 and oxidative stress, and
increased circulating bioavailable VEGF [28]. However, in
this in vivo model, it was not possible to determine the
direct eﬀects of HO-1 and the individual metabolites on the
regulation of each of these factors within the placenta. In
the present work, we have utilized a previously established
model of placental vascular bundle culturing to determine
the importance of each of these factors in the regulation of
oxidative stress and sFlt-1 in response to hypoxia.
Western blotting analysis demonstrated that hypoxia
exposure signiﬁcantly decreased the expression of HO-1 inInternational Journal of Hypertension 5
the vascular bundles. This is surprising, as numerous reports
haveindicatedhypoxia inducesanincreaseinHO-1[41–43].
However,thiseﬀecthasneverbeenexaminedintheplacental
vasculature. This could help explain the increase in oxidative
stress in the preeclamptic placenta. CoPP administration
had no eﬀect under normoxic conditions but in hypoxia
restored HO-1 to normoxic levels. This is consistent with
our previous data which shows that CoPP induces HO-1
in the placenta only with the secondary insult of placental
ischemia/hypoxia [28].
In response to hypoxia exposure, the placental explants
exhibited increased production of sFlt-1. CoPP administra-
tion signiﬁcantly decreased sFlt-1 secretion to levels which
were below even normoxic controls. Though CO has been
showntonegativelyregulateVEGFandinterferon-γ-induced
sFlt-1 in placental explants [27], its eﬀect on hypoxia-
induced sFlt-1 release has not been reported. As suggested
in the literature, CO did indeed signiﬁcantly attenuate
hypoxia-induced sFlt-1, returning to levels equivalent to
CoPP induction. Perhaps most surprisingly, administration
of bilirubin also signiﬁcantly decreased the secretion of sFlt-
1 during hypoxia. This may suggest that oxidative stress
is playing a role in the induction of sFlt-1, though the s
ameliorative eﬀect of bilirubin was not as great as either
CoPP or CO, suggesting that CO is the major factor in HO-
1’s eﬀect on sFlt-1.
Superoxide was also increased in the explants exposed
to hypoxia when compared to normoxic controls. Treatment
with CoPP, which does not induce HO-1 expression under
normoxic conditions, had no eﬀect on superoxide levels.
However, under hypoxic conditions where CoPP normalizes
HO-1 levels, there was a signiﬁcant reduction in the amount
of superoxide produced by the explants. Tellingly, the
exogenous application of bilirubin to the explants under
either normoxic or hypoxic conditions led to a signiﬁcant
decrease in superoxide when compared to their respective
controls. This is perhaps an intuitive result given the known
antioxidant properties of bilirubin but strongly suggests that
moderate elevations in bilirubin production as a result of
increased HO-1 are driving the reduction in oxidative stress.
This demonstrates a second pathway through which HO-1
induction is directly aﬀecting hypoxia-induced changes in
the placental vasculature. It seems evident from these data
as a whole, that HO-1 induction, through both CO and
bilirubinproduction,ishavingadirecteﬀectontheplacental
vasculatureduringischemia/hypoxia.Continuedstudiesinto
the safety and eﬃcacy of agents to increase HO-1 or deliver
these metabolites directly is warranted.
5. Conclusions
We have demonstrated here that induction of HO-1, or
delivery of its bioactive metabolites CO and bilirubin, is
capable of signiﬁcantly downregulating two major hypoxia-
induced factors (oxidative stress and sFlt-1) implicated in
the etiology of preeclampsia. This suggests a promising
therapeutic approach for the treatment of preeclampsia.
Future studies both in vitro and in vivo are necessary to fully
elucidate the therapeutic potential of this approach.
Acknowledgments
The authors would like to thank Kathy Cockrell and Marietta
Arany for their technical expertise. This work was supported
by NIH Grants HL105324-01, HL51971, and HL108618-
01 and a postdoctoral fellowship from the American Heart
Association.
References
[1] J. M. Roberts and D. W. Cooper, “Pathogenesis and genetics of
pre-eclampsia,” Lancet, vol. 357, no. 9249, pp. 53–56, 2001.
[2] J. M. Roberts, G. Pearson, J. Cutler, and M. Lindheimer,
“Summary of the NHLBI Working Group on research on
hypertension during pregnancy,” Hypertension,v o l .4 1 ,n o .3 ,
pp. 437–445, 2003.
[3] K. H. Lim, Y. Zhou, M. Janatpour et al., “Human cytotropho-
blast diﬀerentiation/invasion is abnormal in pre-eclampsia,”
American Journal of Pathology, vol. 151, no. 6, pp. 1809–1818,
1997.
[4] I. A. Brosens, W. B. Robertson, and H. G. Dixon, “The role
of the spiral arteries in the pathogenesis of preeclampsia,”
Obstetrics and Gynecology Annual, vol. 1, pp. 177–191, 1972.
[5] Y. Khong and I. Brosens, “Defective deep placentation,” Best
Practice and Research: Clinical Obstetrics and Gynaecology, vol.
25, no. 3, pp. 301–311, 2011.
[ 6 ]J .M .R o b e r t s ,R .N .T a y l o r ,T .J .M u s c i ,G .M .R o d g e r s ,C .A .
Hubel, and M. K. McLaughlin, “Preeclampsia: an endothelial
cell disorder,” American Journal of Obstetrics and Gynecology,
vol. 161, no. 5, pp. 1200–1204, 1989.
[ 7 ]J .S .G i l b e r t ,M .J .R y a n ,B .B .L a m a r c a ,M .S e d e e k ,S .R .
Murphy, and J. P. Granger, “Pathophysiology of hypertension
duringpreeclampsia:linkingplacentalischemiawithendothe-
lial dysfunction,” American Journal of Physiology, vol. 294, no.
2, pp. H541–H550, 2008.
[8] B.J.Ballermann,“Glomerularendothelialcelldiﬀerentiation,”
Kidney International, vol. 67, no. 5, pp. 1668–1671, 2005.
[9] F. T. H. Wu, M. O. Stefanini, F. M. Gabhann, C. D. Kontos,
B .H .A n n e x ,a n dA .S .P o p e l ,“ As y s t e m sb i o l o g yp e r s p e c t i v e
on sVEGFR1: its biological function, pathogenic role and
therapeutic use,” Journal of Cellular and Molecular Medicine,
vol. 14, no. 3, pp. 528–552, 2010.
[10] T. Nagamatsu, T. Fujii, M. Kusumi et al., “Cytotrophoblasts
up-regulate soluble Fms-like tyrosine kinase-1 expression
under reduced oxygen: an implication for the placental vas-
cular development and the pathophysiology of preeclampsia,”
Endocrinology, vol. 145, no. 11, pp. 4838–4845, 2004.
[11] S. Ahmad and A. Ahmed, “Elevated placental soluble vascular
endothelial growth factor receptor-1 inhibits angiogenesis in
preeclampsia,” Circulation Research, vol. 95, no. 9, pp. 884–
891, 2004.
[12] O. Nevo, N. Soleymanlou, Y. Wu et al., “Increased expression
of sFlt-1 in in vivo and in vitro models of human placental
hypoxiaismediatedbyHIF-1,”AmericanJournalofPhysiology,
vol. 291, no. 4, pp. R1085–R1093, 2006.
[13] R. J. Levine, C. Lam, C. Qian et al., “Soluble endoglin and
other circulating antiangiogenic factors in preeclampsia,” New
England Journal of Medicine, vol. 355, no. 10, pp. 992–1005,
2006.
[14] R. J. Levine, S. E. Maynard, C. Qian et al., “Circulating
angiogenic factors and the risk of preeclampsia,” New England
Journal of Medicine, vol. 350, no. 7, pp. 672–683, 2004.6 International Journal of Hypertension
[15] S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute
to endothelial dysfunction hypertension, and proteinuria in
preeclampsia,” Journal of Clinical Investigation, vol. 111, no. 5,
pp. 649–658, 2003.
[16] J. S. Gilbert, S. A. Babcock, and J. P. Granger, “Hypertension
produced by reduced uterine perfusion in pregnant rats is
associated with increased soluble fms-like tyrosine kinase-1
expression,” Hypertension, vol. 50, no. 6, pp. 1142–1147, 2007.
[17] A. Makris, C. Thornton, J. Thompson et al., “Uteroplacental
ischemia results in proteinuric hypertension and elevated
sFLT-1,” Kidney International, vol. 71, no. 10, pp. 977–984,
2007.
[ 1 8 ]S .R .M u r p h y ,B .B .D .L a m a r c a ,K .C o c k r e l l ,a n dJ .P .
Granger, “Role of endothelin in mediating soluble fms-like
tyrosine kinase 1-induced hypertension in pregnant rats,”
Hypertension, vol. 55, no. 2, pp. 394–398, 2010.
[ 1 9 ]T .H .H u n g ,J .N .S k e p p e r ,D .S .C h a r n o c k - J o n e s ,a n dG .J .
Burton, “Hypoxia-reoxygenation: a potent inducer of apop-
totic changes in the human placenta and possible etiological
factor in preeclampsia,” Circulation Research, vol. 90, no. 12,
pp. 1274–1281, 2002.
[20] A. C. Staﬀ, T. Ranheim, J. Khoury, and T. Henriksen,
“Increased contents of phospholipids, cholesterol, and lipid
peroxides in decidua basalis in women with preeclampsia,”
American Journal of Obstetrics and Gynecology, vol. 180, no.
3, pp. 587–592, 1999.
[21] A. M. Roggensack, Y. Zhang, and S. T. Davidge, “Evidence
for peroxynitrite formation in the vasculature of women with
preeclampsia,” Hypertension, vol. 33, no. 1, pp. 83–89, 1999.
[22] M. Sedeek, J. S. Gilbert, B. B. Lamarca et al., “Role of reactive
oxygen species in hypertension produced by reduced uterine
perfusion in pregnant rats,” American Journal of Hypertension,
vol. 21, no. 10, pp. 1152–1156, 2008.
[23] M. H. Sedeek, Y. Wang, and J. P. Granger, “Increased oxidative
stress in a rat model of preeclampsia,” American Journal of
Hypertension, vol. 17, no. Issue 5, supplement, p. S142, 2004.
[24] J. Neuzil and R. Stocker, “Bilirubin attenuates radical-
mediated damage to serum albumin,” FEBS Letters, vol. 331,
no. 3, pp. 281–284, 1993.
[25] J. Neuzil and R. Stocker, “Free and albumin-bound bilirubin
are eﬃcient co-antioxidants for α- tocopherol, inhibiting
plasma and low density lipoprotein lipid peroxidation,” Jour-
nal of Biological Chemistry, vol. 269, no. 24, pp. 16712–16719,
1994.
[26] L. Wu and R. Wang, “Carbon monoxide: endogenous pro-
duction, physiological functions, and pharmacological appli-
cations,” Pharmacological Reviews, vol. 57, no. 4, pp. 585–630,
2005.
[27] M. Cudmore, S. Ahmad, B. Al-Ani et al., “Negative regula-
tion of soluble Flt-1 and soluble endoglin release by heme
oxygenase-1,” Circulation, vol. 115, no. 13, pp. 1789–1797,
2007.
[28] E.M.George,K.Cockrell,M.Aranay,E.Csongradi,D.E.Stec,
and J. P. Granger, “Induction of heme oxygenase 1 attenuates
placental ischemia-induced hypertension,” Hypertension, vol.
57, no. 5, pp. 941–948, 2011.
[29] E. M. George, K. Cockrell, T. H. Adair, and J. P. Granger,
“Regulation of sFlt-1 and VEGF secretion by adenosine under
hypoxic conditions in rat placental villous explants,” American
Journal of Physiology, vol. 299, no. 6, pp. R1629–R1633, 2010.
[ 3 0 ]I .C a n i g g i a ,C .V .T a y l o r ,J .W .K .R i t c h i e ,S .J .L y e ,a n dM .
Letarte, “Endoglin regulates trophoblast diﬀerentiation along
the invasive pathway in human placental villous explants,”
Endocrinology, vol. 138, no. 11, pp. 4977–4988, 1997.
[31] J. E. Clark, P. Naughton, S. Shurey et al., “Cardioprotec-
tive actions by a water-soluble carbon monoxide-releasing
molecule,” Circulation research, vol. 93, no. 2, pp. e2–e8, 2003.
[32] C. Rudolph, G. Adam, and A. Simm, “Determination of copy
number of c-Myc protein per cell by quantitative Western
blotting,” Analytical Biochemistry, vol. 269, no. 1, pp. 66–71,
1999.
[33] H.M.Peshavariya,G.J.Dusting,andS.Selemidis,“Analysisof
dihydroethidiumﬂuorescenceforthedetectionofintracellular
and extracellular superoxide produced by NADPH oxidase,”
Free Radical Research, vol. 41, no. 6, pp. 699–712, 2007.
[34] J. J. Walker, “Pre-eclampsia,” Lancet, vol. 356, no. 9237, pp.
1260–1265, 2000.
[35] K. Zandi-Nejad, V. A. Luyckx, and B. M. Brenner, “Adult
hypertension and kidney disease: the role of fetal program-
ming,” Hypertension, vol. 47, no. 3, pp. 502–508, 2006.
[36] J. Cao, K. Inoue, X. Li, G. Drummond, and N. G. Abraham,
“Physiological signiﬁcance of heme oxygenase in hyperten-
sion,” International Journal of Biochemistry and Cell Biology,
vol. 41, no. 5, pp. 1025–1033, 2009.
[ 3 7 ]F .T .B o t r o s ,M .L .S c h w a r t z m a n ,C .T .S t i e r ,A .I .G o o d m a n ,
and N. G. Abraham, “Increase in heme oxygenase-1 levels
ameliorates renovascular hypertension,” Kidney International,
vol. 68, no. 6, pp. 2745–2755, 2005.
[38] H. E. Sabaawy, F. Zhang, X. Nguyen et al., “Human heme
oxygenase-1genetransferlowersbloodpressureandpromotes
growth in spontaneously hypertensive rats,” Hypertension, vol.
38, no. 2, pp. 210–215, 2001.
[39] L. Yang, S. Quan, A. Nasjletti, M. Laniado-Schwartzman,
and N. G. Abraham, “Heme oxygenase-1 gene expression
modulates angiotensin II-induced increase in blood pressure,”
Hypertension, vol. 43, no. 6, pp. 1221–1226, 2004.
[40] T. Morita and S. Kourembanas, “Endothelial cell expression
of vasoconstrictors and growth factors is regulated by smooth
muscle cell-derived carbon monoxide,” Journal of Clinical
Investigation, vol. 96, no. 6, pp. 2676–2682, 1995.
[41] M. V. Panchenko, H. W. Farber, and J. H. Korn, “Induction
of heme oxygenase-1 by hypoxia and free radicals in human
dermal ﬁbroblasts,” American Journal of Physiology, vol. 278,
no. 1, pp. C92–C101, 2000.
[42] R. Motterlini, R. Foresti, R. Bassi, V. Calabrese, J. E. Clark,
and C. J. Green, “Endothelial heme oxygenase-1 induction by
hypoxia. Modulation by inducible nitric-oxide synthase and
S-nitrosothiols,” Journal of Biological Chemistry, vol. 275, no.
18, pp. 13613–13620, 2000.
[43] M. S. Carraway, A. J. Ghio, J. D. Carter, and C. A. Piantadosi,
“Expression of heme oxygenase-1 in the lung in chronic
hypoxia,” American Journal of Physiology, vol. 278, no. 4, pp.
L806–L812, 2000.